ArticleIn vitro cellular & developmental biology. Animal2025
Inhibitory effects of carbohydrazide indole derivative on micro-blood vessel growth using ex vivo, in vivo, and in vitro assays.
Article in In vitro cellular & developmental biology. Animal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Topical ronomilast alone or combined with clobetasol ameliorates imiquimod-induced psoriasis in mice.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Defective angiogenesis is a characteristic of many diseases, notably cancer and immune-mediated conditions. Numerous shortcomings in anti-angiogenic therapies, including undesirable effects, drug resistance, and cancer recurrence, encouraged the development of innovative medicines with improved anti-angiogenic efficacy. Indole analogues are thought to interact with the mitotic spindle, preventing malignant human cells from multiplying and invading. N'-(1-Benzyl-2-oxoindolin-3-ylidene)-5-bromo-1H-indole-2-carbohydrazide (N-5-BIC) represents one of these chemicals exhibiting remarkable anti-angiogenesis and anti-proliferation features. The study aimed to investigate the antiangiogenic, antioxidant, and antiproliferative activities of a carbohydrazide indole derivative, N-5-BIC. The ex vivo rat aorta ring (RAR), DPPH, and chick chorioallantois membrane (CAM) assays were employed to assess the N-5-BIC antiangiogenic and antioxidant activities. The MTT assay investigated the anti-proliferative activity in the human umbilical vascular endothelial cells (HUVEC) cell line. The VEGF gene expression level in the colon cancer (HCT116) cell line was evaluated using quantitative real-time polymerase chain reaction (RT-PCR). N-5-BIC demonstrated a substantial and dose-dependent inhibition of blood vessel growth, resulting in an 87.37% reduction at a concentration of 100 μg/ml compared to the negative control (DMSO 1%) in the RAR assay. Additionally, N-5-BIC exhibited a significant decrease in DPPH free radicals in a concentration-dependent manner, with an IC50 value of 129.6 µg/ml. The in vivo CAM assay confirmed a significant regression in blood vessels compared to the negative control. Furthermore, N-5-BIC demonstrated low to non-toxic effects on the HUVEC cell line, with an IC50 value of 1681 μg/ml. The RT-PCR study revealed a significant reduction in VEGF gene expression at doses of 200 and 400 µg/ml as compared to control cells. N-5-BIC has resilient anti-angiogenic properties, which may be attributed to its extensive anti-proliferative and free radical neutralizing properties.
Indexed as
Identifiers
40048112What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.